In this trial, we investigate the efficacy of a new kind of chemotherapy that penetrates the tumor cell specifically. As a result, it should improve the prognosis for patients with triple-negative breast cancer. This kind of cancer is different from other breast cancer because it is significantly more aggressive and the prognosis is worse. Moreover, women affected by this disease are rather young.
For this trial, we use so called “Anti-EGFR-Immunoliposome”. Health authorities have not yet approved its usage. However, it was already investigated in an earlier trial with 26 patients with different tumors. Our trial is the first one that investigates its effectiveness in advanced triple-negative breast cancer.
An anti-EGFR-Immunoliposome composes two main elements, namely chemotherapy (liposomal doxorubicin) and an antibody (cetuximab). Antibodies are protein molecules, which are produced by the human immune system, in order to repel infections. These antibodies are placed on the surface of liposomes (fat molecules that serve as means of transport) and transfer the chemotherapy directly into tumor cells, in order to save the healthy tissue.